预约演示

更新于：2025-01-23

Mild persistent asthma

轻度持续性哮喘

更新于：2025-01-23

基本信息

别名

Asthma, mild persistent、Mild persistent asthma、Mild persistent asthma (disorder)

+ [3]

简介-

关联

项与轻度持续性哮喘相关的药物

Nadolol

纳多洛尔

靶点

p53

作用机制

p53刺激剂

在研机构

Sumitomo Pharma Co., Ltd. [+1]

原研机构

MDD US Operations LLC

在研适应症

原发性高血压 [+6]

非在研适应症

慢性咳嗽 [+3]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1979-12-10

Grass pollen allergy immunotherapy(Laboratorios LETI SL)

靶点-

作用机制

免疫调节剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

项与轻度持续性哮喘相关的临床试验

CTR20244600

/ Active, not recruitingN/A

布地奈德吸入气雾剂人体药代动力学生物等效性（PK-BE）研究

主要研究目的：以Chiesi GmbH持证的布地奈德吸入气雾剂（规格：200μg/揿）为参比制剂，以鲁南贝特制药有限公司研制的布地奈德吸入气雾剂（规格：200μg/揿）为受试制剂，考察两制剂在空腹状态下单次给药吸收速度和程度的差异，评价两制剂是否具有生物等效性。次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。

开始日期2024-12-30

申办/合作机构

鲁南贝特制药有限公司

CTRI/2024/11/076950

/ Not yet recruiting临床1/2期IIT

Effect of Yogic Practice versus Core Stabilisation Exercises on Functional Capacity in children with Asthma: A Randomised Clinical Trial. - NIL

开始日期2024-12-16

申办/合作机构-

CTRI/2024/11/076181

/ Not yet recruitingN/A

A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients with Stable Mild Asthma. - NIL

开始日期2024-11-05

申办/合作机构-

100 项与轻度持续性哮喘相关的临床结果

登录后查看更多信息

100 项与轻度持续性哮喘相关的转化医学

登录后查看更多信息

0 项与轻度持续性哮喘相关的专利（医药）

登录后查看更多信息

项与轻度持续性哮喘相关的文献（医药）

2024-12-01·Heart Rhythm

Asthma is associated with higher recurrence rates of atrial fibrillation after catheter ablation

Article

作者: Lu, Ree ; Dizon, Jose M ; Saluja, Amardeep S ; Gasmelseed, Ahmed Y ; Garan, Hasan ; Skoll, Devin ; Rubin, Geoffrey A ; Yarmohammadi, Hirad ; Biviano, Angelo ; Wan, Elaine Y

BACKGROUNDAsthma is a known risk factor for atrial fibrillation (AF), the most common sustained arrhythmia. Whereas radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.OBJECTIVEThe purpose of this study was to evaluate the impact of asthma and its severity on AF recurrence after ablation.METHODSIn this single-center retrospective case-control study, 63 case patients with AF and asthma who underwent ablation were matched with 126 controls with AF but without asthma who underwent ablation. Case patients were also compared with a nonablated cohort of patients with asthma. AF recurrence was compared between groups. Univariate and multivariate analyses were conducted to determine associations with recurrence.RESULTSCompared with controls who underwent ablation, patients with asthma, particularly those with severe asthma, had a higher likelihood of AF recurrence after catheter ablation (odds ratio, 3.76 [P = .047] and 5.06 [P = .041], respectively). However, case patients were not more likely to experience adverse outcomes. Multivariate analysis revealed that persistent AF and use of a beta blocker were associated with recurrence. Patients with moderate or severe persistent asthma were more likely than patients with intermittent or mild persistent asthma to have left atrial enlargement (odds ratio, 2.53; P = .009).CONCLUSIONPatients with AF and asthma, particularly those with severe asthma, were more likely than patients with AF but without asthma to have AF recurrence after ablation. Patients with AF and severe asthma were also more likely to have severe left atrial enlargement, a known predictor of recurrence after ablation.

2023-05-01·Computers in biology and medicine

Bioinformatics analysis of ferroptosis-related gene AKR1C3 as a potential biomarker of asthma and its identification in BEAS-2B cells.

Article

作者: Weng, Cuiye ; Tong, Yu ; Wang, Yufei ; Song, Jingjing ; Zhang, Weixi ; Fan, Junwen ; Wang, Lingya ; Wang, Lei ; Lai, Chuqiao

Ferroptosis is a newly discovered type of cell death and has recently been shown to be associated with asthma. However, the relationship between them at the genetic level has not been elucidated via informatics analysis. In this study, bioinformatics analyses are conducted using asthma and ferroptosis datasets to identify candidate ferroptosis-related genes using the R software. Weighted gene co-expression network analysis is performed to identify co-expressed genes. Protein-protein interaction networks, the Kyoto encyclopedia of genes and genomes, and gene ontology enrichment analysis are used to identify the potential functions of the candidate genes. We experimentally validate the results of our analysis using small interfering RNAs and plasmids to silence and upregulate the expression of the candidate gene in human bronchial epithelial cells (BEAS-2B). The ferroptosis signature levels are examined. Bioinformatics analysis of the asthma dataset GDS4896 shows that the level of the aldo-keto reductase family 1 member C3 (AKR1C3) gene in the peripheral blood of patients with severe therapy-resistant asthma and controlled persistent mild asthma (MA) is significantly upregulated. The AUC values for asthma diagnosis and MA are 0.823 and 0.915, respectively. The diagnostic value of AKR1C3 is verified using the GSE64913 dataset. The gene module of AKR1C3 is evident in MA and functions through redox reactions and metabolic processes. Ferroptosis indicators are downregulated by the overexpression of AKR1C3 and upregulated by silencing AKR1C3. The ferroptosis-related gene AKR1C3 can be used as a diagnostic biomarker for asthma, particularly for MA, and regulates ferroptosis in BEAS-2B cells.

2022-01-01·Pediatric Allergy and Immunology1区 · 医学

Controversies in the treatment of mild asthma. What novelties and practical implications?

1区 · 医学

Review

作者: Licari, Amelia ; Tosca, Maria Angela ; Leone, Maddalena ; Di Cicco, Maria Elisa ; Scavone, Maria

AbstractMild asthma is prevalent in childhood and causes as many as 30%–40% asthma exacerbations requiring emergency visits. The management of "intermittent" and "mild persistent" asthma phenotypes is still a matter of debate, even if the role of inhaled corticosteroids, both continuous and intermittent, is a cornerstone in this field. Recent updates of the guidelines on the strategies to manage these patients are coming, since the role of inflammation in these asthma phenotypes is crucial, as well as the potential side effect and risks of short‐acting beta 2 agonists overuse, prescribed as the only "as‐needed" treatments. In this paper, we overview the new (r)evolution regarding intermittent and mild persistent asthma management.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。